Copanlisib - Bayer HealthCare Pharmaceuticals

Drug Profile

Copanlisib - Bayer HealthCare Pharmaceuticals

Alternative Names: Aliqopa; BAY-806946; BAY-841236; Copanlisib hydrochloride

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer All Ireland Cooperative Oncology Research Group; Bayer HealthCare Pharmaceuticals; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (USA)
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Morpholines; Pyrimidines; Quinazolines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Marginal-zone-B-cell-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Follicular lymphoma
  • Phase III Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Phase II Cholangiocarcinoma; Diffuse large B cell lymphoma; Endometrial cancer; Mantle-cell lymphoma
  • Phase I/II Breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 13 Mar 2018 Bayer plans a phase I/II trial for Solid tumours (Recurrent, In infants, In children, In adolescents, In adults) in USA in April 2018 (NCT03458728)
  • 19 Jan 2018 Bayer completes a phase II trial in Diffuse large B cell lymphoma (Second-line therapy or greater) in Canada, Australia, the UK, Belgium, France, Germany, Denmark, Spain, Italy, Turkey, South Korea and Singapore (EudraCT2014-004848-36) (NCT02391116)
  • 09 Jan 2018 Copanlisib is not yet launched for Follicular lymphoma in USA (Literature review)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top